# Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in PAD Patients.

> **NCT04229264** · PHASE3 · UNKNOWN · sponsor: **Science Valley Research Institute** · enrollment: 200 (estimated)

## Conditions studied

- Critical Limb Ischemia

## Interventions

- **DRUG:** Apixaban
- **DRUG:** ASA
- **DRUG:** Clopidogrel 75mg

## Key facts

- **NCT ID:** NCT04229264
- **Lead sponsor:** Science Valley Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-09
- **Primary completion:** 2022-02-02
- **Final completion:** 2022-05-02
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2021-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04229264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04229264, "Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in PAD Patients.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04229264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*